Cholesterol drug may calm inflammation after heart attack

NCT ID NCT03515304

Completed Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether evolocumab (Repatha), a drug that lowers LDL cholesterol, can reduce inflammation and improve heart function in people who recently had a mild heart attack (NSTEMI). Sixty participants received either evolocumab or a placebo within 24 hours of admission. The main goals were to measure changes in cholesterol levels and inflammation in the heart using PET scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Evolocumab (Repatha), a drug that lowers LDL cholesterol
What this could lead to: If successful, this could show that adding evolocumab right after a heart attack reduces inflammation and improves heart recovery.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply broadly. The drug is already approved for cholesterol lowering, but its benefit in acute heart attack settings is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome acute subendocardial myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME

Contacts and locations

Locations

Steven Paul Schulman

Baltimore, Maryland, 21136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.